Hematologic Malignancies Program

UMGCC Named Center of Excellence by Myelodysplastic Syndromes Foundation

Ask the Expert
Get answers to your Myelodysplastic Syndromes questions.
Dr. Baer’s Bio | Q&A Archive
Note: This is for informational purposes only. Doctors cannot provide a diagnosis or individual treatment advice via e-mail. Please consult your physician about your specific health care concerns.

Please install flash player to see this video.
Cancer Center Virtual Tour
Related Content
Hematologic Malignancies Program
Myelodysplastic Syndromes
Cancer Overviews
Our Doctors

The University of Maryland Marlene and Stewart Greenebaum Cancer Center has been designated as a Center of Excellence by the Myelodysplastic Syndromes Foundation.

To be recognized as a Center of Excellence for treatment in myelodysplastic syndromes (MDS), a hospital must have:

An established university (or equivalent) program
Recognized morphologic expertise in MDS
Available cytogenetics and/or molecular genetics
Ongoing research, including Institutional Review Board-approved clinical trials
Documentation of peer-reviewed publications in the field
The ability and intention to register patients in the MDS International Registry Database

For More Information:

About Myelodysplastic Syndromes

Hematologic Malignancies Program

This page was last updated on: October 7, 2009.